Bloomberg "Anywhere" Remote Login Bloomberg "Terminal" Request a Demo

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $0.31 USD
Change Today +0.041 / 15.07%
Volume 7.2M
ETRM On Other Exchanges
Symbol
Exchange
NASDAQ CM
Frankfurt
As of 3:11 PM 09/2/15 All times are local (Market data is delayed by at least 15 minutes).

enteromedics inc (ETRM) Snapshot

Open
$0.39
Previous Close
$0.27
Day High
$0.39
Day Low
$0.28
52 Week High
01/14/15 - $2.05
52 Week Low
08/24/15 - $0.20
Market Cap
33.3M
Average Volume 10 Days
1.2M
EPS TTM
$-0.37
Shares Outstanding
106.4M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ENTEROMEDICS INC (ETRM)

enteromedics inc (ETRM) Related Businessweek News

No Related Businessweek News Found

enteromedics inc (ETRM) Details

EnteroMedics Inc., a medical device company, focuses on the design and development of devices that use neuroblocking technology to treat obesity, metabolic diseases, and other gastrointestinal disorders. The company’s proprietary neuroblocking technology is designed to intermittently block the vagus nerve using electrical impulses. It develops the Maestro Rechargeable System, which is used to limit the expansion of the stomach, control hunger sensations between meals, reduce the frequency and intensity of stomach contractions, and produce a feeling of early and prolonged fullness. The company is evaluating the Maestro System in human clinical trials in the United States, Australia, and Mexico. It has collaboration with Mayo Clinic for the development and testing of products for the treatment of obesity. The company was formerly known as Beta Medical, Inc. and changed its name to EnteroMedics Inc. in 2003. EnteroMedics Inc. was founded in 2002 and is headquartered in St. Paul, Minnesota.

28 Employees
Last Reported Date: 03/13/15
Founded in 2002

enteromedics inc (ETRM) Top Compensated Officers

Founder, Chairman, Chief Executive Officer an...
Total Annual Compensation: $410.2K
Co-Founder and Vice President of Clinical & R...
Total Annual Compensation: $297.2K
Chief Financial Officer, Chief Operating Offi...
Total Annual Compensation: $338.3K
Senior Vice President of Research and Advance...
Total Annual Compensation: $296.6K
Compensation as of Fiscal Year 2014.

enteromedics inc (ETRM) Key Developments

EnteroMedics Inc., Board Meeting, Aug 20, 2015

EnteroMedics Inc., Board Meeting, Aug 20, 2015. Agenda: To consider the retirement of Mark B. Knudson as Chief Executive Officer ( CEO ) and President as of December 31, 2015.

EnteroMedics Inc. Announces Management Changes

EnteroMedics Inc. announced that Mark B. Knudson, Ph.D., EnteroMedics Founder, Chairman, President and Chief Executive Officer notified the company of his intention to retire effective December 31, 2015. Dr. Knudson will remain Chairman of the EnteroMedics Board of Directors. The company also announced that Jon Tremmel, a member of the company's board of directors, has been appointed as Consultant to the CEO. Mr. Tremmel will lead a search committee to find a successor for the chief executive role as well as provide strategic advice to the company regarding its commercialization and reimbursement activities during the transition.

EnteroMedics Receives Non-Compliance Notice From Nasdaq

On August 12, 2015, EnteroMedics Inc. received a written notice from the Listing Qualifications department of The Nasdaq Stock Market (Nasdaq) indicating that the Company is not in compliance with the $1.00 Minimum Bid Price requirement set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on the Nasdaq Capital Market. The Nasdaq Listing Rules require listed securities to maintain a minimum bid price of $1.00 per share and, based upon the closing bid price for the last 30 consecutive business days, the Company no longer meets this requirement. The Notice indicated that the Company will be provided 180 calendar days in which to regain compliance. If at any time during this period the bid price of the Company’s common stock closes at or above $1.00 per share for a minimum of ten consecutive business days, the Nasdaq Staff will provide the Company with a written confirmation of compliance and the matter will be closed. In the event the Company does not regain compliance with Rule 5550(a)(2) prior to the expiration of the 180 calendar day period, the Nasdaq Staff will provide the Company with written notification that its securities are subject to delisting from The Nasdaq Capital Market. At that time, the Company may appeal the delisting determination to a Hearings Panel. Alternatively, if the Company fails to regain compliance with Rule 5550(a)(2) prior to the expiration of the 180 calendar day period, but meets the continued listing requirement for market value of publicly held shares and all of the other applicable standards for initial listing on The Nasdaq Capital Market, with the exception of the minimum bid price, and provides written notice of its intention to cure the deficiency during the second compliance period by effecting a reverse stock split, if necessary, then the Company may be granted an additional 180 calendar days to regain compliance with Rule 5550(a)(2). The Company is actively monitoring its performance with respect to the listing standards and is currently considering available options to resolve the deficiency and regain compliance with the Nasdaq rules.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ETRM:US $0.31 USD +0.041

ETRM Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ETRM.
View Industry Companies
 

Industry Analysis

ETRM

Industry Average

Valuation ETRM Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 256.2x
Price/Book 14.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales 293.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ENTEROMEDICS INC, please visit www.enteromedics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.